Successful desensitization to oxaliplatin with incorporation of calcium gluconate and magnesium sulfate

Anti-Cancer Drugs

Volumn 18, Issue 6, 2007, Pages 721-724

  Wrzesinski, Stephen H ^a   McGurk, Meghan L ^a   Donovan, Constance T ^a   Ferencz, Thomas M ^a   Saif, Muhammad Wasif ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calcium gluconate and magnesium sulfate; Desensitization; Oxaliplatin

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; FLUOROURACIL; FOLINIC ACID; GLUCONATE CALCIUM; HYDROCORTISONE; MAGNESIUM SULFATE; METOPROLOL; ONDANSETRON; OXALIPLATIN; PALONOSETRON;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLOATING; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CASE REPORT; CLINICAL TRIAL; COLON ADENOCARCINOMA; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DESENSITIZATION; DIARRHEA; DRUG HYPERSENSITIVITY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEADACHE; HEART ATRIUM FIBRILLATION; HEMICOLECTOMY; HUMAN; IRRITABLE COLON; LYMPH VESSEL; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHIC PAIN; NEUROPATHY; NEUROTOXICITY; PALLOR; PHOTOPHOBIA; PRIORITY JOURNAL; SIGMOID; SYSTOLIC HYPERTENSION; THORAX PAIN; VISUAL IMPAIRMENT; VOMITING;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCIUM GLUCONATE; DRUG HYPERSENSITIVITY; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MAGNESIUM SULFATE; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; SIGMOID NEOPLASMS; TREATMENT OUTCOME;

EID: 34548337046     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32802ffbcb     Document Type: Article

References (16)

1. De Gramont A, Banzi M, Navarrro M, Tabernero T, Hickish J, Bridgewater F, et al. Oxaliplatin/5-FU/LV in adjuvant cancer: Results of the international randomized Mosaic trial. Proc Am Soc Clin Oncol 2003; 22:253.
2. André T, Boni C, Mounedji-Goudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343-2351.
3. Sanofi-Aventis Package Insert. www.eloxatin.com
4. Gammon D, Bhargava P, McCormick M. Hypersensitivity reactions to oxaliplatin and the application of a densitization protocol. The Oncologist 2004; 9:546-549.
5. Mis L, Fernando N, Hurwitz H, Morse M. Successful desensitization to oxaliplatin. Ann Pharmacother 2005; 39:966-969.
6. Ng C. Hypersensitivity reactions to oxaliplatin in two Asian patients. Ann Pharmacother 2005; 39:1114-1118.
7. Gowda A, Goel R, Berdzik J, Leichman CG, Javle M. Hypersensitivity reactions to oxaliplatin: incidence and management. Oncology (Willliston Park) 2004; 18:1671-1675.
8. Hewitt MR, Sun W. Oxaliplatin-associated hypersensitivity reaction: clinical presentation and management. Clin Colorectal Cancer 2006; 6:114-117.
9. Lee MY, Yang MH, Liu JH, Yen CC, Lin PC, Teng HW, et al. Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication. Support Care Cancer 2007; 15:89-93.
10. Thomas RR, Quinn MG, Schuler B, Grem JL. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 2003; 97:2301-2307.
11. Brandi G, Pantaleo M, Galli C, Anonuzzo A, Marco MC. Hypersensitivity reactions to oxaliplatin. Br J Cancer 2003; 89:477-481.
12. Saif MW. Hypersensitivity reactions associated with oxaliplatin. Expert Opin Drug Saf 2006; 5:687-694.
13. Greene FL, Page DL, Fleming ID, Fritz AP, Balch CM, Haller DG, Morrow M, editors. AJCC Cancer Staging Manual, 6th ed. New York: Springer; 2002.
14. Van Cutsem E, Dicato M, Wils J, Cunningham D, Diaz-Rubio E, Glimelius B, et al. Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: perspectives in Colorectal Cancer, Dublin 2001). Eur J Cancer 2002; 38:1429-1436.
15. Gamelin L, Boisdron-Cell M, Delva R, Guerin-Meyer V, Ifrah N, Morel A, Gamelin E. Prevention of oxaliplatin-related neurotoxicity by calcium magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin of advanced colorectal cancer. Clin Can Res 2004; 10:4055-4061.
16. Merkel S, Mansmann U, Papadopoulos T, Wittekind C, Hohenberger W, Hermanek P. The prognostic inhomogeneity of colorectal carcinomas Stage III. A proposal for subdivision of Stage III. Cancer 2001; 92:2754-2749.